Someone asked about Regentys and the progress...
Post# of 36568
(Total Views: 388)
Posted On: 06/15/2020 3:52:41 PM
Someone asked about Regentys and the progress...
Looks like they have been dead in the water in 2020 so far. And:
"As a condition of its licensing agreement with the University of Pittsburgh, Regentys has specific milestones to meet in its development program in 2020 or its exclusive license can be terminated. Funding is required to retain this license. Should this license be lost, Regentys would have options to develop its co-developed technology with Pittsburgh, but the company would likely have to repeat research to use a new form of hydrogel process to make its product without infringing the University of Pittsburgh’s patent. This would be a substantial additional cost to Regentys and create a competitive advantage to any new holder in due course of such rights. In addition, Regentys has additional patents in process that could serve as the basis of additional regenerative medicine products in the urogenital space, but additional research and development is required. Any delay in funding could substantial delay these projects in time and increase costs." (page 54)
So they would presumably need to get the train rolling soon to meet these "specific milestones" in 2020.
This is a fascinating product, so I sure hope we don't lose the handle on this one.
Looks like they have been dead in the water in 2020 so far. And:
"As a condition of its licensing agreement with the University of Pittsburgh, Regentys has specific milestones to meet in its development program in 2020 or its exclusive license can be terminated. Funding is required to retain this license. Should this license be lost, Regentys would have options to develop its co-developed technology with Pittsburgh, but the company would likely have to repeat research to use a new form of hydrogel process to make its product without infringing the University of Pittsburgh’s patent. This would be a substantial additional cost to Regentys and create a competitive advantage to any new holder in due course of such rights. In addition, Regentys has additional patents in process that could serve as the basis of additional regenerative medicine products in the urogenital space, but additional research and development is required. Any delay in funding could substantial delay these projects in time and increase costs." (page 54)
So they would presumably need to get the train rolling soon to meet these "specific milestones" in 2020.
This is a fascinating product, so I sure hope we don't lose the handle on this one.
(1)
(0)